ARX517

Janssen Research & Development, LLC · Phase 1 active Small molecule

At a glance

Generic name	ARX517
Sponsor	Janssen Research & Development, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (PHASE1)
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARX517 CI brief — competitive landscape report
ARX517 updates RSS · CI watch RSS
Janssen Research & Development, LLC portfolio CI